In 1995, Harold E. Varmus, who was then the director of the National Institutes of Health (NIH), convened the NIH Director's Panel on Clinical Research. The panel was charged with making recommendations to foster the NIH's support of clinical research, a field that was pervaded by discouragement and believed to be in jeopardy. [1] [2] [3] [4] The panel met between July 1995 and November 1997, when it issued a series of recommendations. 2, 5 In this article, we review these recommendations, inventory the changes made within the NIH and in clinicalresearch portfolios within the private sector since 1995, and assess the effects of these changes.
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The panel defined clinical research as studies of living human subjects, including the laboratory-based development of new forms of technology; studies of the mechanisms of human disease and evaluations of therapeutic interventions (which are known collectively as translational research); clinical trials, outcome studies, and health care research; and epidemiologic and behavioral studies. 2 The definition excluded disease-oriented studies of tissue samples obtained from individual patients or groups of patients who were unknown to the investigators. On the basis of this definition of clinical research, the panel recommended the establishment of programs for clinical-research training of medical students, postgraduate training programs (funded by K30 grants) in the methods and ethics of clinical research, research grant support for young clinical investigators (funded by K23 grants), grant support for experienced clinical researchers who act as mentors (funded by K24 grants), the restructuring of the study sections that review applications for clinical-research grants, increased responsibility within the General Clinical Research Center program for ensuring the high quality of clinical research, and educational-debt relief for young clinical investigators, including those who are members of minority groups. 2 The panel invited private foundations and pharmaceutical and health insurance corporations to assume strong, supporting roles in these recommended endeavors.
spending for clinical research
Before 1996, when the NIH began to measure its expenditures for clinical research, the only indexes of such spending were derived indirectly, from assessments of the number of grants awarded to physicians in any given year and from the budgets for clinical trials of the individual institutes. Neither index is reliable. Clinical trials represent only about one third of the NIH's expenditures for clinical research. Furthermore, whereas researchers with Ph.D. degrees are the principal investigators for many NIHfunded clinical studies, the panel was particularly concerned about the support of translational (benchto-bedside) research, which is more likely to be conducted by physicians.
the clinical-research portfolio
The panel's first task was to develop a working definition of clinical research that would permit NIH staff to make an inventory of expenditures by the NIH for clinical research. The panel studied the abstracts of the proposals for all the competitive grants that were awarded in 1996 and found that approximately 27 percent of the awards and 38 percent of the dollars were devoted to clinical research as the panel had defined it (Table 1) . 2 The NIH has subsequently continued to use such a system to track its expenditures for clinical investigation. As shown in Table 1 , the commitment has been well maintained. Between 1996 and 2001, the total number of competitive NIH awards increased by approximately 40 percent, and the dollars awarded increased by almost 100 percent. The percentage of these awards and dollars devoted to clinical research, however, remained constant, at about 25 percent and 34 percent, respectively. The consistent support for clinical research during a five-year period of substantial growth in funding by the NIH suggests that the availability of research funds was a source of optimism among clinical and basic scientists alike. In addition, the consistency of the support suggests that the interests of applicants for funding and the function of the peer-review system were unchanged.
The ratio of applications submitted to the NIH by Ph.D. and M.D. investigators for individual research projects (77 percent of which were investigator-initiated individual grants, or R01s) gradually increased from 1.0 in 1965 to 2.6 in 1979, and it has remained approximately 2.5 since 1990. 2 The average annual increase in the number of competitive applications from physicians before 1990 (2.3 percent) was roughly half the annual increase in the number of applications from Ph.D. investigators (4.0 percent), but the success rates for the two groups were similar (data not shown). The high ratio of Ph.D. applicants to M.D. applicants reflects the strong commitment of the NIH to basic biomedical science, the commitment of holders of the Ph.D. degree to research careers, and the increase in the number of Ph.D. degrees awarded in the biomedical sciences. The panel's efforts had no influence on these ratios. 2
first-time applicants and their renewal rates
The number of first-time applicants for NIH research grants (largely R01s) has varied since 1990, 5 but from 1996 through 2001 it increased by 23 percent for M.D. researchers, 50 percent for those with both the M.D. and Ph.D. degrees, and 29 percent for Ph.D. researchers (Fig. 1) . During this five-year period, increases in the NIH's budget induced both new and established investigators to submit grant requests. The average success rates (including those for revised and resubmitted applications in this period) were 27 percent, 34 percent, and 33 percent, respectively, for these three groups of applicants. The success rate for first-time applicants with Ph.D.s was consistently higher than that for first-time applicants who were physicians, and the success rate for first-time applicants was lower than that for established investigators. Although the number of clinical investigators in each of the three groups of applicants is not known, many NIH-supported clinical investigators hold the Ph.D. degree alone.
The only year for which long-term outcome data * The awards include grants for research projects, training grants, career awards, and contracts. R01s (investigator-initiated grants) accounted for 46 to 47 percent of these awards. are available with regard to first-time recipients of research grants from the NIH is 1996 ( for an overall success rate of 44 percent for investigators and 53 percent for awards. In the nonclinical category, the overall success rates for individuals and for awards were 55 percent and 63 percent. Although this sample is necessarily smallbecause it is too soon to assemble reliable data for years after 1996 -the results suggest a substantial decrease in the number of researchers in all categories who applied for grants after receiving a firsttime grant from the NIH and, in particular, a large decrease in the number of clinical investigators (81 percent). The data suggest that the discrepancy in funding clinical research and nonclinical research in the NIH's grants competition is not solely a result of unequal treatment of applications for clinicalresearch grants. Perhaps clinical-research projects are completed more rapidly than basic research projects; there may be other reasons for investigators' failure to reapply. Nevertheless, the ratio of awards for clinical research to those for basic research will not increase if clinical investigators fail to apply and reapply and if the success rates for applications and reapplications remain consistently below the rates for applications by basic scientists.
new clinical-research grants
Most members of the panel held that the ratio of expenditures for basic research to expenditures for clinical investigations that characterized the NIH's extramural portfolio -approximately 2:1 -was appropriate for federal support of biomedical research. Advances in clinical research depend on expanded knowledge of basic science, but many basic science projects do not find a practical application. Therefore, the panel believed that the best way to increase commitments to clinical research in the NIH portfolio was to increase the total budget of the NIH. Fortunately, Congress agreed.
Yet the panel also concluded that one type of clinical investigation did not receive sufficient support from the NIH -namely, research at the interface between basic science and clinical application, or translational research. The panel based this conclusion on the members' experience of the conduct of study sections. The understandable bias in favor of basic research on the part of study sections made up largely of basic scientists made it difficult for clinical applications to be funded. Interviews with young investigators in many academic medical centers, conducted by Dr. Lawrence Schulman of the NIH staff in 1996, confirmed the pressing need to rectify this problem, 6 and to that end, the panel recommended the establishment of NIH grant programs for young clinical investigators and for their mentors, regardless of whether the overall NIH budget was increased.
Accordingly, two types of grants, K23 grants for young investigators and K24 grants for clinical investigators who act as mentors, were introduced (Table 3 ). In 1999 through 2001, the NIH received over 1400 applications for K23 or K24 support, most of them requests from physicians, whose success rates approached 50 percent. The dollars committed to the K23, K24, and K30 programs were a small fraction of the total extramural NIH budget, but they have had a large effect on clinical research. The * R01s (investigator-initiated individual grants) accounted for approximately 77 percent of applications for clinical-research grants. The number of awards exceeds the total number of applicants because some applicants who were awarded grants in 1996 applied for both type 1 and type 2 grants. (Table 5) . These developments reflect an increased awareness in the private and public sectors of the need to support clinical research. 7
reorganization of study sections
The NIH panel also addressed the makeup of the study sections that review translational investigations. In the course of the panel's deliberations, Ellie Ehrenfeld, Ph.D., director of the NIH Center for Scientific Review, undertook an evaluation of the study sections and instituted major changes in their organization and composition. In particular, it was decided that clinical-research applications would be reviewed by the study sections that review a large proportion of clinical applications. Theodore A. Kotchen, M.D., was appointed as adviser for review of clinical research, and changes in the organization of the review process were instituted. As a result, six study sections now deal almost exclusively with patient-oriented research, including the sections for clinical oncology and the cardiovascular sciences. In approximately 25 additional study sections, more than 75 percent of grant applications involve research with human subjects, including studies of psychology, epidemiology, nursing, and behavior that puts persons at risk for disease. Moreover, the entire system of study sections is undergoing reor- ganization (with completion expected in two to three years), with the goal of assuring that at least 25 percent of clinical applications will be reviewed in all study sections that review clinical applications and that all such study sections will include clinical investigators. The Center for Scientific Review has developed specific guidelines for peer review of applications for clinical-research grants and plans to track the outcome of these reviews.
training in clinical research
A substantial part of the NIH panel's attention was focused on training. Reasoning that an interest in careers in clinical research should begin in medical school, 8 the panel recommended the establishment of a program to provide medical students with experience in clinical research on the NIH campus, and a proposal was swiftly implemented with the support of Pfizer. Since 1996, 85 medical students have spent at least one year in clinical research at the NIH, and it is hoped that many will devote their careers to clinical research. The Doris Duke Charitable Foundation also made a commitment to the training of clinical investigators, including support at 10 institutions for training programs in which a total of 65 medical students were enrolled in 2002. It is anticipated that many of these students will eventually join research training programs and that many will choose careers in clinical research. The panel also recommended that the NIH award grants for didactic training programs in clinical research (K30 grants) at academic medical centers. Fifty-seven such grants have been awarded, and the NIH has begun to assess the effect of these programs on the training of research fellows. Surely, the knowledge base of clinical researchers of the future is in the process of expansion.
educational-loan relief
The panel addressed the burden that educational debt imposes on physicians who aspire to academic careers. In particular, the increase in the average educational debt makes it difficult for young physicians to spend the required amount of time as trainees or junior faculty members. The panel did not offer a firm recommendation in this difficult area, other than to state that clinical researchers who are members of minority groups are badly needed in academic medicine. Fortunately, other members of the academic medical community have addressed this issue, and with the support of members of Congress such as Senator Edward M. Kennedy (D-Mass.) and Representative Nita M. Lowey (D-N.Y.), a bill to provide a competitive loan-relief program for eligible clinical researchers, pediatricians, and minority-group members was passed (the Public Health Improvement Act of 2000). 9, 10 In 2002, $30 million was committed to the NIH's educational-loan-relief program, with the stipulation that clinical researchers had to hold a K23 (young-investigator) award; of 766 applications reviewed, 55 percent of those from members of minority groups and 80 percent of other applications were approved. There may be several reasons for the lower-than-expected number of applications. The most likely reason is that the requirements for eligibility for this program were too stringent; in 2003 they were relaxed for non-minority-group applicants. The new eligibility requirements include a half-time commitment to research for two years, The panel considered the role of the General Clinical Research Centers in the approximately 70 academic health centers in which they are located. The staff members of the centers understand protocol design and the issues of safety and integrity in clinical research, and they undergo periodic, in-depth, peer review to ensure the productivity and integrity of research at the centers. If the numbers of support personnel within these staffs could be enlarged, the centers would be well placed to take responsibility for the quality and integrity of clinical research in the host institutions. This increase in staffing might prevent some of the serious accidents that may occur in clinical research, which on occasion have brought an unfortunate notoriety to the field. The General Clinical Research Centers have already instituted research-advocacy positions as a step toward strengthening oversight of the clinical research conducted at these sites. But academic health centers must make every effort to support the infrastructure of clinical research as well as they support that of basic research, [11] [12] [13] and they need to make certain that their relations with the pharmaceutical industry are free of conflicts of interest. [14] [15] [16] The Director's Panel on Clinical Research provided a description of clinical investigation that has made it possible to define the actual clinical-research portfolio of the NIH's extramural program. The consequence has been a reinforcement of the importance and value of clinical research in academic medicine. Other interested groups have joined this effort, as shown by the establishment of the educationalloan-relief program and steps taken by private foundations and at least one pharmaceutical company to support clinical investigation and training. The net result of these efforts has been to diminish the aura of discouragement and crisis surrounding clinical investigation. But continued, careful attention to the support of clinical research by academic health centers, private foundations, the pharmaceutical industry, and the NIH remains crucial. In addition, investigators as well as academic health centers must pay particular heed to research ethics and to potential conflicts of interest, so that the reputation of clinical research is not sullied.
